



• After 18 hours attachment, cells were
treated with adenosine analogues (10µM)
for one hours. Then cells were washed and
adsorbed with virus for another hour
(MOI: 0.1). After one hour virus
adsorption, cells were washed and
cultured for 5 days in cell culture medium.
• After five days, virus titer in each well was
determined by dilution method.
Vaccines against infectious viral diseases
are good in preventing those illnesses,
however their application is not
recommended in curing the ongoing
infection. Antiviral drugs such as
nucleotide analogs have been successfully
used in treating various viral infections.
Current study is designed to evaluate the
antiviral efficacy of adenosine analogues
such as Remdesivir, Galidesivir, and 2-
Chloroadenosine in inhibiting the human
(HOC43) replication by interfering viral
RNA dependent RNA polymerase (RdRp)
activity.
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1.
Materials and Methods 
Department of Biology, University of
Dayton , Dayton for providing funding for
this project.
• RNA dependent RNA polymerase gene
(RdRp) sequence for Human
Coronavirus OC43 (HCoV-OC43) was
obtained from National Center for
Biotechnology Information (NCBI) data
base.
• Molecular docking using Maestro
software was performed to determine
the interaction of adenosine analogues
with viral RdRp.
• Invitro efficacy of adenosine analogues
such as Remdesivir, Galidesivir, and 2-
Chloroadenosine (Cayman Chemical,
Ann Arbor, MI) in reducing HCoV-OC43
(ATCC, Manassas, VA) replication was
performed in 6 cell plates using HCT-8
cells .




• Molecular docking results showed that
adenosine analogues such as Remdesivir,
Galidesivir, and 2-Chloroadenosine
efficiently interact with HCoV-OC43 RdRp
(Figure 1)
• In vitro results showed that Remdesivir,
Galidesivir, and 2-Chloroadenosine
significate reduced HCoV-OC43 titer
(log10) such as 1.00±0.00/ml,
1.33±0.57/ml and 1.33±0.57/ml
respectively as compare to untreated
control cells (5.00± 0.00/ml) (n=3)
(Figure 2 A and 2B)
Figure 1. Molecular docking using Maestro
software indicating the interaction of
adenosine (A), Remdesivir (B) and
Galidesivir (C) with RdRp.
Figure 2. Adenosine analogues significantly 
reduced the virus titer as measured 
cytopathic effect under microscope (A) as 
well as cell staining by 1%  crystal violet   (B).
• All adenosine analogues used in current
study significantly reduced HCoV-OC43
replication.
• Replicates the experiment for
reproducibility.
• Determining lowest effect doses for each
adenosine analogues in reducing HCoV-
OC43 replication.
• Determining their effect on RdRp activity.
